Professional Analysts at Baird Reiterated their “Outperform” rating for Sarepta Therapeutics (SRPT). The Target Price is Set to $202; DIAMONDCORP PLC ORD 0.1P (LON:DCP) Covered By 3 Bullish Analysts Last Week

June 21, 2018 - By Michael Collier

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Among 5 analysts covering Diamondcorp PLC (LON:DCP), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Diamondcorp PLC had 43 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by SP Angel on Wednesday, December 16 with “Buy”. Northland Capital maintained the stock with “Buy” rating in Thursday, November 12 report. On Thursday, July 28 the stock rating was reinitiated by Panmure Gordon with “Buy”. The firm has “Speculative Buy” rating given on Monday, November 7 by SP Angel. Panmure Gordon maintained it with “Buy” rating and GBX 14.50 target in Tuesday, June 14 report. The firm has “Buy” rating by SP Angel given on Tuesday, October 13. Panmure Gordon maintained DIAMONDCORP PLC ORD 0.1P (LON:DCP) on Wednesday, March 2 with “Buy” rating. Panmure Gordon maintained DIAMONDCORP PLC ORD 0.1P (LON:DCP) on Friday, July 31 with “Buy” rating. The stock has “Buy” rating by SP Angel on Tuesday, October 18. The stock of DIAMONDCORP PLC ORD 0.1P (LON:DCP) has “Buy” rating given on Friday, November 20 by Northland Capital. See DIAMONDCORP PLC ORD 0.1P (LON:DCP) latest ratings:

They currently have a $202 TP on Sarepta Therapeutics (NASDAQ:SRPT). Baird’s target would suggest a potential upside of 31.43% from the company’s previous close. This was revealed to clients and investors in an analyst note on 21 June.

It closed at GBX 2.05 lastly. It is down 0.00% since June 21, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical DCP News: ; 15/05/2018 – Venus Medtech Receives DCP Capital’s Equity Investment to Accelerate Heart Valve Technology Development and International; 24/05/2018 – SEMGROUP, DCP CITE DJ BASIN TO MONT BELVIEU NGL PIPELINE; 23/04/2018 – DCP Midstream to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results; 07/05/2018 – SemGroup to Diversify White Cliffs Pipeline Service with NGL Capabilities; Signs Long-Term Contract with DCP Midstream; 21/05/2018 – DCP Midstream Listed as a 2018 Fortune 500 Company; 02/04/2018 – Report: Exploring Fundamental Drivers Behind PetMed Express, DCP Midstream Partners, LP, Gladstone Land, Federated National Hol; 07/05/2018 – DCP Midstream 1Q EPS 8c; 07/05/2018 – DCP MIDSTREAM 1Q OPER REV. $2.14B, EST. $2.51B; 09/05/2018 – DCP Midstream, LP Announces Public Offering of Series B Preferred Units; 09/05/2018 – Fitch Rates DCP Midstream, LP’s Preferred Equity Offering ‘BB-‘/’RR6’

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: which released: “Sarepta Therapeutics: Chasing The Good News” on June 21, 2018, also with their article: “Gene Therapy For Duchenne” published on June 20, 2018, published: “Why Sangamo Therapeutics Stock Is Spiking Today” on June 20, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: and their article: “Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday” published on June 19, 2018 as well as‘s news article titled: “Sarepta Therapeutics (SRPT) PT Raised to $176 at SunTrust Robinson Humphrey” with publication date: June 21, 2018.

The stock increased 6.78% or $9.76 during the last trading session, reaching $153.69. About 4.53 million shares traded or 190.24% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 21, 2017 and is uptrending. It has outperformed by 184.51% the S&P500. Some Historical SRPT News: 16/05/2018 – Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting; 30/03/2018 – Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4); 25/05/2018 – Oncolytics Biotech Collaborates With USC Using Pelareorep in Combination With Keytruda, Velcade and Dexamethasone to Treat Multiple Myeloma; 09/04/2018 – Merck: Keytruda Significantly Improves Overall Survival in Study; 31/05/2018 – Medivir: Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual Meeting; 09/04/2018 – KEYTRUDA MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3; 16/04/2018 – NEARLY 70 PCT OF KEYTRUDA PLUS CHEMOTHERAPY PATIENTS ALIVE AFTER 1 YEAR VS 49 PCT FOR CHEMO ALONE – DATA; 13/03/2018 – Merck Gets FDA Priority Review for Keytruda sBLA in Advanced Cervical Cancer; 09/04/2018 – STAT Plus: Pharmalittle: Novartis pays $9 billion for gene therapy company; Merck’s Keytruda scores a win; 23/05/2018 – MERCK & CO INC – SAFETY PROFILE OF KEYTRUDA IN COMBINATION WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED IN LUNG CANCER

Investors sentiment decreased to 0.97 in Q1 2018. Its down 0.25, from 1.22 in 2017Q4. It fall, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported. 54 are held by Peddock Capital Advsrs Ltd Liability. Envestnet Asset Management Incorporated owns 1,008 shares. Zeke Cap Advisors Lc reported 3,249 shares or 0.02% of all its holdings. Royal Bank & Trust Of Canada holds 288,894 shares or 0.01% of its portfolio. Castleark Mgmt Limited holds 103,178 shares. Stifel Fincl owns 33,436 shares or 0.01% of their US portfolio. Ameritas Inv Incorporated holds 0.02% or 5,161 shares. North Star Inv Mngmt Corporation reported 935 shares. Proshare Advsrs Limited Co owns 0.02% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 37,696 shares. Federated Investors Pa reported 53,369 shares. Sectoral Asset Management owns 327,698 shares. Hsbc Holding Public Limited Com owns 3,110 shares or 0% of their US portfolio. Weiss Multi owns 64,500 shares. Pinnacle Assocs Ltd reported 290,121 shares. Driehaus Cap Management Limited holds 0.14% or 54,529 shares in its portfolio.

Among 28 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 23 have Buy rating, 0 Sell and 5 Hold. Therefore 82% are positive. Sarepta Therapeutics has $267 highest and $4 lowest target. $97.92’s average target is -36.29% below currents $153.69 stock price. Sarepta Therapeutics had 126 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, September 19 by Janney Capital. On Friday, April 29 the stock rating was downgraded by Jefferies to “Underperform”. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Outperform” rating given on Tuesday, March 13 by Credit Suisse. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, October 28 report. RBC Capital Markets maintained the shares of SRPT in report on Friday, December 16 with “Outperform” rating. Cowen & Co maintained it with “Buy” rating and $69.0 target in Monday, September 4 report. The rating was maintained by Piper Jaffray with “Buy” on Friday, March 2. As per Thursday, October 26, the company rating was maintained by Barclays Capital. Wedbush downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday, April 21 to “Neutral” rating. The firm has “Outperform” rating given on Monday, October 10 by Wedbush.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $10.07 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: